scholarly journals The Philosophical and Evidentiary Basis of Homoeopathic Immunisation: a Response to Teixeira

2021 ◽  
Vol 13 (46) ◽  
pp. 45-53
Author(s):  
Isaac Golden
Keyword(s):  
Adverse Effects ◽  
Disease Prevention ◽  
Scientific Evidence ◽  
Double Standard ◽  
Short Term ◽  
Toxic Damage ◽  
Prophylactic Use

Homeopathic immunisation was first used in 1798, but remains controversial with some homeopathic practitioners. Teixeira supported the use of genus epidemicus (GE) remedies, but strongly condemned the use of nosodes for disease prevention. However Teixeira failed to fully understand the Principal of Similars, he used a double standard when comparing evidence using GE remedies and nosodes, he misread information demonstrating the safety of long-term HP, and he appeared to be unaware of scientific evidence which is available supporting the prophylactic use of nosodes. These four areas are addressed in turn, and evidence from 1798 to 2012 is presented showing that appropriate homoeopathic immunisation using GE remedies and/or nosodes has the potential to prevent much suffering without any risk of possible short-term toxic damage or long-term energetic adverse effects.

Oil pollution and fisheries

1982 ◽  
Vol 297 (1087) ◽  
pp. 401-411 ◽  
Keyword(s):  
Water Quality ◽  
Adverse Effects ◽  
Oil Pollution ◽  
Coastal Areas ◽  
Short Term ◽  
Fish Stocks ◽  
Local Impacts ◽  
Reduced Water ◽  
Long Term Adverse Effects

The term ‘pollution’ is taken in its broadest sense and effects are recognized to be due to interference, tainting and toxicity. Each of these types of impact is discussed and assessed. It is concluded that no long-term adverse effects on fish stocks can be attributed to oil but that local impacts can be extremely damaging in the short term and that produce from specific localities can be tainted and unmarketable for long periods. In some coastal areas oil can be one among several contributors to reduced water quality, and the implications of this are discussed.

scholarly journals Symposium report: breast cancer in India—trends, environmental exposures and clinical implications

2021 ◽  
Vol 32 (6) ◽  
pp. 567-575
Author(s):  
Jasmine A. McDonald ◽  
Roshni Rao ◽  
Marley Gibbons ◽  
Rajiv Janardhanan ◽  
Surinder Jaswal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Scientific Evidence ◽  
Treatment Options ◽  
Environmental Exposures ◽  
Population Based ◽  
Clinical Implications ◽  
Think Tank ◽  
Case Control Studies ◽  
Short Term

Abstract Purpose Incidence of breast cancer (BC), particularly in young women, are rising in India. Without population-based mammography screening, rising rates cannot be attributed to screening. Investigations are needed to understand the potential drivers of this trend. Methods An international team of experts convened to discuss the trends, environmental exposures, and clinical implications associated with BC in India and outlined recommendations for its management. Results Panels were structured across three major BC themes (n = 10 presentations). The symposium concluded with a semi-structured Think Tank designed to elicit short-term and long-term goals that could address the challenges of BC in India. Conclusion There was consensus that the prevalence of late-stage BC and the high BC mortality rates are associated with the practice of detection, which is primarily through clinical and self-breast exams, as opposed to mammography. Triple-Negative BC (TNBC) was extensively discussed, including TNBC etiology and potential risk factors, the limited treatment options, and if reported TNBC rates are supported by rigorous scientific evidence. The Think Tank session yielded long-term and short-term goals to further BC reduction in India and included more regional etiological studies on environmental exposures using existing India-based cohorts and case–control studies, standardization for molecular subtyping of BC cases, and improving the public’s awareness of breast health.

scholarly journals The Immune System Can Hear Noise

2021 ◽  
Vol 11 ◽  
Author(s):  
Andi Zhang ◽  
Tianyuan Zou ◽  
Dongye Guo ◽  
Quan Wang ◽  
Yilin Shen ◽  
...  
Keyword(s):  
Immune System ◽  
Adverse Effects ◽  
Immune Function ◽  
Noise Exposure ◽  
The Body ◽  
Intensity Noise ◽  
Short Term ◽  
Non Hodgkin Lymphoma ◽  
Exposure During Pregnancy

As a stressor widely existing in daily life, noise can cause great alterations to the immune system and result in many physical and mental disorders, including noise-induced deafness, sleep disorders, cardiovascular diseases, endocrine diseases and other problems. The immune system plays a major role in maintaining homeostasis by recognizing and removing harmful substances in the body. Many studies have shown that noise may play vital roles in the occurrence and development of some immune diseases. In humans, both innate immunity and specific immunity can be influenced by noise, and different exposure durations and intensities of noise may exert various effects on the immune system. Short-term or low-intensity noise can enhance immune function, while long-term or high-intensity noise suppresses it. Noise can lead to the occurrence of noise-induced hearing loss (NIHL) through the production of autoantibodies such as anti-Hsp70 and anti-Hsp60 and exert adverse effects related to other immune-related diseases such as some autoimmune diseases and non-Hodgkin lymphoma. The neuroendocrine system, mainly including the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenal-medullary (SAM) system, is involved in the mechanisms of immune-related diseases induced by noise and gut microbiota dysfunction. In addition, noise exposure during pregnancy may be harmful to the immune system of the fetus. On the other hand, some studies have shown that music can improve immune function and alleviate the adverse effects caused by noise.

scholarly journals New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients

2015 ◽  
Vol 60 (2) ◽  
pp. 833-837 ◽  
Author(s):  
María Gabriela Álvarez ◽  
Yolanda Hernández ◽  
Graciela Bertocchi ◽  
Marisa Fernández ◽  
Bruno Lococo ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Effects ◽  
Liver Enzymes ◽  
Main Criterion ◽  
Short Term ◽  
Follow Up Study ◽  
End Of Treatment ◽  
Chronic Chagas Disease

ABSTRACTThere is a clinical need to test new schemes of benznidazole administration that are expected to be at least as effective as the current therapeutic scheme but safer. This study assessed a new scheme of benznidazole administration in chronic Chagas disease patients. A pilot study with intermittent doses of benznidazole at 5 mg/kg/day in two daily doses every 5 days for a total of 60 days was designed. The main criterion of response was the comparison of quantitative PCR (qPCR) findings prior to and 1 week after the end of treatment. The safety profile was assessed by the rate of suspensions and severity of adverse effects. Twenty patients were analyzed for safety, while qPCR was tested for 17 of them. The average age was 43 ± 7.9 years; 55% were female. Sixty-five percent of treated subjects showed detectable qPCR results prior to treatment of 1.45 (0.63 to 2.81) and 2.1 (1.18 to 2.78) parasitic equivalents per milliliter of blood (par.eq/ml) for kinetoplastic DNA (kDNA) qPCR and nuclear repetitive sequence satellite DNA (SatDNA) qPCR, respectively. One patient showed detectable PCR at the end of treatment (1/17), corresponding to 6% treatment failure, compared with 11/17 (65%) patients pretreatment (P= 0.01). Adverse effects were present in 10/20 (50%) patients, but in only one case was treatment suspended. Eight patients showed mild adverse effects, whereas moderate reactions with increased liver enzymes were observed in two patients. The main accomplishment of this pilot study is the promising low rate of treatment suspension. Intermittent administration of benznidazole emerges a new potential therapeutic scheme, the efficacy of which should be confirmed by long-term assessment posttreatment.

scholarly journals Charms & Harms: Devil's Claw

2009 ◽  
Vol 1 (3) ◽  
pp. 238 ◽  
Author(s):  
Joanne Barnes
Keyword(s):  
Adverse Effects ◽  
Herbal Medicines ◽  
Term Treatment ◽  
Low Back ◽  
Efficacy And Safety ◽  
Short Term ◽  
Short Term Treatment ◽  
Acute Exacerbations ◽  
Long Term Adverse Effects

SUMMARY MESSAGE: There is evidence that Devil’s Claw can be an effective short-term treatment for acute exacerbations of low back pain and, to a lesser extent, in rheumatic and osteoarthritic conditions. Acute adverse effects reported in clinical trials were mild diarrhoea and flatulence. Long-term adverse effects have not been studied. As with all herbal medicines, Devil’s Claw products differ in their pharmaceutical quality, and the implications of this for efficacy and safety should be considered.

The Carcinogen in Our Daily Life - A Cross-Sectional Study

2021 ◽  
Vol 8 (7) ◽  
pp. 223-227
Author(s):  
Rani Nallathamby ◽  
Boban Babu ◽  
Meril Ann Soman
Keyword(s):  
Adverse Effects ◽  
Teaching Hospital ◽  
Daily Life ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Short Term ◽  
Cross Sectional ◽  
Large Teaching Hospital ◽  
Safe Limit

Objective: To study about the awareness of toxic effects of Formaldehyde in Chronic users Design: Questionnaire study. Questionnaires were sent to chronic formaldehyde users and responses were analysed. Setting: Large teaching hospital-various medical colleges in south Karnataka and Kerala. Results: Most of the participants are aware about the adverse effects of formaldehyde but they are unaware of the major carcinogenic and teratogenic risks. Most of the participants don’t know the safe limit of exposure to formaldehyde and most of them don’t care whether the exhaust fans are working or windows are open. Majority of the participants had experienced the short term effects of formaldehyde whereas only 67 had experienced long term sequelae. Keywords: Formaldehyde, Carcinogen, Embalming.

A Decreased Incidence of Necrotizing Enterocolitis After Prenatal Glucocorticoid Therapy

PEDIATRICS ◽  
1984 ◽  
Vol 73 (5) ◽  
pp. 682-688 ◽  
Author(s):  
Charles R. Bauer ◽  
John C. Morrison ◽  
W. Kenneth Poole ◽  
Sheldon B. Korones ◽  
John J. Boehm ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Necrotizing Enterocolitis ◽  
Steroid Therapy ◽  
Short Term ◽  
Antenatal Corticosteroids ◽  
Lung Maturation ◽  
Intestinal Maturation ◽  
Blinded Trial ◽  
Long Term Adverse Effects

In a large multicentered, collaborative randomized and blinded trial utilizing antenatal corticosteroids, the goals included determining the effectiveness of these agents in accelerating lung maturation, as well as monitoring any short-term or long-term adverse effects of this treatment on the parturient, fetus, and/or infant. More than 100 specific items, pertaining to diagnoses, complications, and outcomes were recorded for the 696 mothers enrolled in the study and their 745 infants. A significantly decreased incidence of necrotizing enterocolitis (P = .002) was found in the infants treated with steroids. The possibility of accelerated intestinal maturation induced by antenatal maternal steroid therapy exists. This treatment regimen is particularly attractive as adverse aspects of steroid therapy at the dosage utilized have not been demonstrated.

Safety of ciclesonide in children with asthma: A review of randomized controlled trials

2021 ◽  
Vol 42 (6) ◽  
pp. 471-480 ◽  
Author(s):  
Michael Blaiss ◽  
William Berger ◽  
Bradley Chipps ◽  
Vivian Hernandez-Trujillo ◽  
Wanda Phipatanakul ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Randomized Controlled Trials ◽  
Hpa Axis ◽  
Growth Velocity ◽  
Controlled Trials ◽  
Short Term ◽  
Randomized Controlled ◽  
Children With Asthma ◽  
Asthma In Children

Background: Parental concerns about the adverse effects of asthma medications can lead to nonadherence and uncontrolled asthma in children. Ciclesonide (CIC) is a prodrug, with low oropharyngeal deposition and bioavailability that may minimize the risk of local and systemic adverse effects. CIC is U.S. Food and Drug Administration approved for asthma in children ages ≥ 12 years. Objective: To summarize safety results from the 13 phase II or III randomized controlled trials conducted in children with asthma during CIC clinical development. Methods: Four 12- to 24-week trials compared the safety of once-daily CIC 40, 80, or 160 µg/day with placebo; four 12-week trials compared the safety of CIC 80 or 160 µg/day with either fluticasone or budesonide; one 12-month trial compared the long-term safety of CIC 40, 80, or 160 µg/day with fluticasone; one 12-month trial compared growth velocity of CIC 40 or 160 µg/day with placebo; and three cross-over trials compared short-term growth velocity and hypothalamic-pituitary-adrenal (HPA) axis effects of CIC 40, 80, or 160 µg/day with placebo or fluticasone. Results: In all, 4399 children were treated with CIC. The incidence of treatment-emergent adverse events (AE) was similar among the CIC doses and between CIC and placebo in short-term studies and between CIC and fluticasone in the long-term safety study. No CIC-related serious AEs were reported in any study. The incidence of treatment-related oral candidiasis was low and similar between CIC (≤0.5%) and placebo (≤0.7%) or active controls (≤0.5%) in the short-term studies. There was no clinically relevant HPA axis suppression or reduction in growth velocity associated with CIC. Conclusion: Data from 13 studies demonstrate that CIC is associated with low rates of oropharyngeal AEs, with no indication of clinically relevant systemic effects in children with asthma. The favorable safety profile and demonstrated improvements in asthma control make CIC an ideal inhaled corticosteroid for the treatment of asthma in children.

scholarly journals Gold Standard of Symptomatic treatment in Parkinson disease: Carbidopa / Levodopa

2018 ◽  
pp. 63-68 ◽  
Author(s):  
Aslam Pathan ◽  
Abdulrahman Alshahrani
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adverse Effects ◽  
Gold Standard ◽  
Signs And Symptoms ◽  
Symptomatic Treatment ◽  
Short Term ◽  
Neurologic Disorders ◽  
Pharmacological Data

Parkinson's disease (PD) is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed but not halted, by treatment. The goal of the medical management of Parkinson's disease is to provide control of signs and symptoms for as long as possible while minimizing adverse effects. Levodopa coupled with a peripheral decarboxylase inhibitor (PDI), such as carbidopa, remains the gold standard of symptomatic treatment of motor features of Parkinson's disease. It provides the greatest antiparkinsonian benefit with the fewest adverse effects in the short term. However, its long-term use is associated with the development of fluctuations and dyskinesias. This review article is written to summarize the clinical and pharmacological data of carbidopa and levodopa which will be helpful to neurologists and physicians.

Sign in / Sign up

Export Citation Format

Share Document